OWC Pharmaceutical Research Corp, Letter to Shareholders

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a letter to shareholders.
Stock Symbols

OWC Pharmaceutical Research Corp. to Attend Biotech Showcase 2019

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, announced today that management will attend Biotech Showcase 2019 to be held in San Francisco, CA on January 7-9, 2019.
Stock Symbols

OWC Pharmaceutical Research Corp Reports Progress in Clinical Trials for Ointment Care for Skin Diseases

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, reported today that the last healthy volunteer in its first ever safety study of cannabis-based topical ointment, was recently admitted in trial which is being conducted at Sheba Medical Center, Tel Hashomer, Israel. Mr. Mordechai Bignitz, OWC Pharmaceutical CEO commented: ” We are extremely pleased with the progress on this trial. Recruiting has now been completed and we expect to complete the trial by the end of December”.
Stock Symbols

OWC Pharmaceutical Research Corp. to Report Progress in Clinical Trials for Ointment Care for Skin Diseases

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, reported today that the safety study of cannabis-based topical ointment, conducted at Shiba Shiba Academic Medical Center, is close to completion as the last healthy volunteer started the treatment three weeks ago. The subject of study is expected to be treated with the ointment during six weeks.
Stock Symbols

OWC Pharmaceutical Research Corp. to Meet With Investors, Researchers and Business Partners at 2018 MJBizCon; Revealing the Testing of Novel Formulation for Multiple Myeloma Therapy

RAMAT GAN, Israel, Nov. 6, 2018 /PRNewswire/ — Subsequent to its recent announcement [https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-successfully-142200823.html] of the successful tests of its innovative delivery formulation aimed at Multiple Myeloma therapy, OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, announced today that the company’s management will be attending the 2018 MJBizCon [https://mjbizconference.com/vegas/] (Marijuana Business Conference), to be held at Las Vegas Convention Center, on November 14-16, 2018.
Stock Symbols

OWC Pharmaceutical Research Corp Successfully Tests Unique, Innovative Delivery Formulation Aimed at Multiple Myeloma Therapy

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that our newly developed, highly concentrated, delivery formulation, OWC-1808, was administered in vivo in an animal model for the first time and was found to be safe and tolerable. This formulation will allow the delivery of very high doses of CBD and THC with exceptional bioavailability. The continued development and testing of this formulation will be directed initially at our ongoing program for treating Multiple Myeloma.
Stock Symbols